Sight Sciences, Inc. SGHT

SGHT Company Overview

Sight Sciences, Inc. is a U.S.-based medical device company focused on developing and commercializing minimally invasive technologies for ophthalmic care, primarily targeting glaucoma and dry eye disease. The company operates within the ophthalmology and medical technology industries and generates revenue primarily through the sale of surgical devices and related consumables used by ophthalmologists and eye care professionals. Its principal commercial offerings include the OMNI Surgical System and SION Surgical Instrument for glaucoma procedures, as well as the TearCare System for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction.

The company was founded in 2010 and is headquartered in Menlo Park, California. Sight Sciences evolved from an early-stage ophthalmic device developer into a publicly traded medical technology company following increased adoption of minimally invasive glaucoma surgery (MIGS) procedures in the United States. Its strategic positioning centers on providing interventional technologies designed to address the underlying causes of prevalent eye diseases rather than relying solely on chronic pharmaceutical management. Public disclosures, including SEC filings and investor materials, consistently identify ophthalmologists and ambulatory surgery centers as core customer groups.